Markets
Kiora Pharmaceuticals, Inc. (KPRX)
KPRXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.51
+0.0800 (+5.59%) today
Closed, Nov 9, 4:00 PM ET
+5.59% 1D
- Market cap
- $6.68m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.40 to $2.91
- Average volume
- 32.2k
- Previous close
- $1.43
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $12.00, +694.7% from here
$12.00now $1.51$12.00
Earnings
Next report
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$794.0k | -$7.31m | -$2.51m | -$2.21m |
| Net income | $27.0k | -$6.52m | -$2.42m | -$2.08m |
News
6 latest- Kiora Pharmaceuticals, Inc. Enters Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. for KIO-401Fintel · Oct 29, 2026
- Kiora Pharma Closes Private Placement For Up To $24 Mln; Stock Up RTTNews · Apr 7, 2026
- Eyes On Kiora - ABACUS-2 And KLARITY Data Readouts Due In 2027 RTTNews · Nov 4, 2025
- Kiora (KPRX) Q2 Revenue Falls 100%The Motley Fool · Aug 8, 2025
- Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should KnowZacks · Jul 16, 2025
- KIORA PHARMACEUTICALS Earnings Results: $KPRX Reports Quarterly EarningsQuiver Quantitative · Mar 25, 2025
The company
Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- kiorapharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.